Abstract Medication adherence is thought to be the principal clinical predictor of positive clinical outcomes, not only for serious mental illnesses such as schizophrenia, bipolar disorder, or depression, but also for physical conditions such as diabetes. Consequently, research on medication often looks not only at medication condition (e.g., placebo, standard medication, investigative medication), but also at adherence in taking those medications within each medication condition. The percentage (or proportion) scale is one of the more frequently employed and easily interpretable measures. Patients can be 0 % adherent, 100 % adherent, or somewhere in between. For simplicity, many reported adherence analyses dichotomize or trichotomize the adherence predictor when estimating its effect on outcomes of interest. However, the methodological literature shows that the practice of categorizing continuously distributed predictors reduces statistical power at best and, at worst, can severely bias parameter estimates. This can result in inflated Type I errors (false positive acceptance of null adherence effects) or Type II errors (false negative rejection of true adherence effects). We extend the methodological literature on categorization to the construct of adherence. The measurement scale of adherence leads to a diverse family of potential distributions including uniform, n-shaped, u-shaped (i.e., bimodal), positively skewed, and negatively skewed. Using a simulation study, we generated negative, null, and positive ''true'' effects of adherence on simulated continuous and binary outcomes. We then estimated the adherence effect with and without categorizing the adherence variable. We show how parameter estimates and standard errors can be severely biased when categorizing adherence. The categorization of adherence is shown to cause null effects to become positive or negative depending on the distribution of the simulated adherence variable, inflating Type I errors. When the adherence effect was significantly different from zero, categorization can render the effect null, inflating Type II errors. We recommend that adherence be measured continuously and analyzed without categorization when using it as a predictor in regression models.
Introduction
Adherence to prescribed medication regimens is thought to improve clinical outcomes and reduce the need for costly interventions, including hospitalizations, which are sometimes necessary to stabilize conditions exacerbated due to outpatient medication nonadherence (Sokol et al., 2005) . Clinical and cost benefits of adherence have been identified for a variety of mental health (Davis et al., 2003; AscherSvanum et al., 2010) and physical (Hepke et al., 2004; Wood et al., 2003; Simpson et al., 2006; Ho et al., 2009) conditions across both individual studies and meta-analytic work. However, there may be reasons to reconsider such findings, principally related to the impact of categorizing continuous measures of adherence when they are modeled as independent variables. Specifically, the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) recommends that any categorization of adherence data should be both clinically justified and subjected to a statistical sensitivity analysis (Peterson et al., 2007) , although this appears to be rare in practice. Of concern, prior methodological research has illustrated that categorizing normally distributed predictors reduces statistical power at best and, at worst, can severely bias parameter estimates (MacCallum et al., 2002) . Biased estimates of the effects of adherence, if they are present, have implications for policy, clinical care, decision models, and efficacy and effectiveness trials. For example, it is estimated that if adherence could be increased by as little as 20 %, annual Medicaid rehospitalization savings would approach $7.5 million (Sun et al., 2007) ; however, it is unclear if these estimates are accurate in light of biases that may result from categorizing medication adherence. In the current study, we attempt to expand on ISPOR recommendations by quantifying the biases resulting from categorizing adherence data via a simulation study.
Measuring adherence
The medication adherence literature reveals that there are multiple ways to measure adherence to a prescribed regimen, that some sort of categorization is undertaken frequently, and that many categorization thresholds are employed. This variability suggests that adherence researchers as a whole are struggling to define adherence in some categorical way, identifying the adherent from the nonadherent.
The measurement of adherence falls into three broad categories: self-report, pill count, and derivation via administrative data. Self-report measures can be simple, such as a binary indicator of adherence to the prescribed regimen on a ''regular'' basis (Svarstad et al., 2001) or some other threshold (e.g., possessing medication 80 % of the days under study) (Olfson et al., 2014; Swartz et al., 1998a, b; Knapp et al., 2004; Swanson et al., 2007) . Some studies develop scales to measure medication adherence (e.g., Yen et al., 2005) , including the Brief Adherence Rating Scale, for example (cf., Byerly et al., 2008) . Others ask respondents the number of days they adhered to their medication over a given time frame and compute the percentage adherent (e.g., Maggiolo et al., 2007) . Semistructured interviews capturing the percentage of doses taken have also been used to estimate adherence (Hommel et al., 2008) .
Pill counts or counts of missed doses allow researchers to determine percent compliance by dividing the number of pills taken by the number prescribed. This approach has been used in psychiatric research (Swanson et al., 2008) , antiretroviral therapy (Ballif et al., 2009) , and cardiovascular disease (Wei et al., 2008) . Alternatively, some studies simply record whether any medication was taken, as done in research on malaria treatment (Onyebuchi et al., 2014) . Medication event monitoring systems, which record the number of times, in addition to the day and time, the bottle was opened have also been used in cancer research (Ibrahim et al., 2011; Ferguson et al., 2005) and psychiatric research (Byerly et al., 2005; Remington et al., 2007; Nakonezny et al., 2008) .
Medical claims or medical possession data are used frequently to construct measures of adherence on a continuous percentage scale. One such example is the medication possession ratio (MPR), which is based on the total days of supply with the denominator being a refill interval, and can take values ranging from 0 to more than 100 %. The MPR has been used in studies of antipsychotics (Van Dorn et al., 2013; Weiden et al., 2004; Valenstein et al., 2006; Ivanova et al., 2012; Gilmer et al., 2004; Valenstein et al., 2002) , hormone therapy (Hsieh et al., 2014; Hershman et al., 2011) , respiratory therapy (Vestbo et al., 2009) , or for multiple health conditions (Sokol et al., 2005; Roebuck et al., 2011) . Another measure used increasingly with medical claims data is the proportion of days covered (PDC), which is frequently used in diabetes research (Nichols et al., 2015; Buysman et al., 2015; Juarez et al., 2013) . PDC values range between 0 and 1 and are based on the total days all drugs were available divided by the days in the follow-up period. As with MPR, the PDC can be multiplied by 100 to transform it to a percentage scale. Measures like MPR or PDC can be computed from medical records, as done for injection antipsychotic adherence (Acosta et al., 2014) .
Categorizing adherence
When categorizing adherence based on adherence measured on a percentage scale, the choice of cut values often appears to be arbitrary and lacking scientific justification (Peterson et al., 2007) . However, increasingly, studies are using an 80 % threshold (Van Dorn et al., 2013; Acosta et al., 2014; Valenstein et al., 2006; Ivanova et al., 2012; Nichols et al., 2015; Buysman et al., 2015; Hommel et al., 2008; Wei et al., 2008; Juarez et al., 2013; Vestbo et al., 2009; Hershman et al., 2011; Roebuck et al., 2011; Valenstein et al., 2002) . Other binary cuts are also used, including 70 % (Weiden et al., 2004) or 85 % (Ibrahim et al., 2011) .
Other studies cut adherence into three or more categories. Trichotomization has been used with cuts at 50 and 80 % (Nichols et al., 2015; Gilmer et al., 2004) . Other studies move beyond three levels, including, for example, categories representing extremely low (\55 %), low (55-75 %), intermediate (76-95 %) , and high ([95 %) levels of adherence, which have been used for AIDS studies (Maggiolo et al., 2007) . Categories of 1-19, 20-39, 40-59, 60-79 , and 80-100 % have been used in hospitalization and antiviral therapy studies (Sokol et al., 2005; Yasuda et al., 2004) . Other studies have used cut points for adherence representing never/almost never (0-25 % of the time), sometimes (26-50 % of the time), usually (51-75 % of the time), and always/almost always (76-100 % of the time; Elbogen et al., 2005) .
Summary of adherence measurement and categorization
In summary, measurement of adherence is often on a proportion scale from 0 to 1, or percentage scale from 0 to 100 %, although many other approaches are used. Frequently, however, the original scaling of the adherence independent variable is categorized, and often it appears, without clinical justification (Peterson et al., 2007) . Although a categorized independent variable may be interpreted more intuitively in a regression model (but see below for how adherence effects can be interpreted incorrectly), including the specification of interaction effects, the risk of potential biased results would suggest that the practice of categorizing adherence, when used as an independent variable, should be limited and implemented only when clinically or empirically justified. As note previously, two of the most common categorizations are dichotomization at 80 % and trichotomization at 50 and 80 %, and we use these conventions in the current study.
The variability in the reported studies suggests that the implicit goal is to cut the continuum of adherence into the adherent and nonadherent, although little empirical work has been done to justify cutting the continuum of adherence. Such efforts are found lacking in the literature, but if they are to be carried out, they will be philosophically challenging and methodologically demanding (Lubke & Tueller, 2010; Lubke & Miller, 2015; Asmundson et al., 2012; Lilienfeld, 2014) . In addition, and as noted previously, the methodological literature has shown that categorizing continuous variables without strong justification likely results in reduced statistical power and increased bias in parameter estimates (MacCallum et al., 2002; Fedoro et al., 2009; DeCoster et al., 2009; Shentu & Xie, 2010) .
The counterintuitive interpretation of parameter estimates when categorizing adherence
In this section, we illustrate how an adherence threshold of, say, 80 %, can be easily misunderstood. At first glance, one might think the effect of adherence dichotomized at 80 % on some outcome can be interpreted as the effect of being 80 % adherent or higher; this is an imprecise and potentially misleading conclusion. To see why, consider the situation where a one-unit increase in adherence (measured continuously on the percentage scale) is associated with a one-unit increase in some outcome (i.e., B 1 = 1). Further consider five different potential adherence distributions, uniform, n-shaped, and u-shaped (see Fig. 1a ) and negatively skewed and positively skewed (see Fig. 1b ). As noted previously, adherence research rarely reports the distribution of adherence. We have observed u-shaped and negatively skewed adherence distributions in prior studies of antipsychotic (Swanson et al., 2006) and statin medications (Pringle et al., 2014) . Using the equation = B 1 9 adherence + e, a population true parameter of B 1 = 1, an effect size R 2 = 0.5, and normally distributed simulated error terms, we simulated the adherence distributions of Fig. 1a , b and constructed normally distributed outcome variables for 1000 participants yielding five data sets, one for each adherence distribution. Three models were fit to the data set for each of the five adherence distributions, first with the continuous adherence predictor shown in Fig. 1a Table 1 . The first thing to notice in Table 1 is that if, in fact, one were estimating the effect of being at least 80 % compliant, the parameter estimates under both binary and tertiary categorizations are highly variable across the shapes of the uncategorized adherence distribution. The second is that the correct population values of B 1 = 1 and R 2 = 0.5 are recaptured when using the continuous adherence predictors. Third, when using the categorized adherence predictors, the estimated R 2 values are all attenuated, ranging from slightly attenuated to the extreme being near zero (R 2 = 0.03 for the binary cut of the positively skewed uncategorized adherence distribution). Finally, the parameter estimates for the effect of dichotomized and trichotomized adherence on the outcome appear at first glance to be extremely overestimated. Specifically, the parameter estimates for uncategorized adherence are near the population value of B 1 = 1 while the categorized estimates are over an order of magnitude larger, ranging from 29.2 to 77.1.
To understand what these large parameter estimates with a categorized adherence predictor actually represent, consider the following: The average of the outcome within each adherence category, which is given in the lower legend of each panel in Fig. 1a , b, can be used to calculate the mean difference between categorizations. These values allow one to see the relationships between these mean differences (which is what is being tested in a t test) and the regression parameter estimates in Table 1 . This is illustrated using the first row of Fig. 1a , the uniform adherence distribution. For the binary categorization, the simulated data produce a mean difference of 87.4-39.4 = 48.0. Note that 48.0 is the parameter estimate for the uniform distribution with the binary cut shown in Table 1 . Hence, B 1 = 48.0 is not the effect of being more than 80 % adherent relative to the effect of being less than 80 % adherent. Rather, it is the difference of an average outcome of 39.4 (i.e., the mean level of the outcome for all those with adherence \80 %) and an average outcome of 87.4 (i.e., the mean level of the outcome for all those with adherence C80 %). Analogously (and noting that the lowest group is the reference category), 64.1-24.8 = 39.3 and 87.4-24.8 = 62.6, where 39.3 and 62.6 appear in the Table 1 under the tertiary cut column. Hence, B 1 = 39.3 is the effect of moving from an average outcome of 24.8 % (i.e., the mean level of the outcome for all those with adherence \50 %) to 64.1 (i.e., the mean level of the outcome for all those with adherence C50 to \80 %) and B 1 = 62.6 is the effect of moving from an average adherence of 24.8-87.4 (i.e., the mean level of the outcome for all those with adherence B80 %).
The illustration of this section shows that one cannot interpret categorized adherence scores as being, for example, the effect of being at least 80 % adherent on any given outcome. Rather, the effect must be interpreted as difference between the average outcome in one adherence category and the average outcome in the reference adherence category. Although this corrected interpretation may enlighten prior and future adherence research, the primary utility of this illustration is pedagogical and has two major limitations. First, for a single sample, this interpretation is most apparent under ideal conditions, for example, when (1) the outcome is continuous, (2) the effect size is large (R 2 C 0.5), (3) the sample size is large (n C 1000), and (4) under bivariate linear regression (or under multiple linear regression with uncorrelated predictors). Second, the categorized effect might not be directly comparable from study to study unless the distribution of adherence is the same between studies. The distribution of adherence is rarely reported, regardless of whether adherence data are categorized. This potentially challenges any meta-analytic work using categorized adherence predictors, cautions future meta-analytic work, and suggests that adherence researchers should start providing the histogram for adherence. Although this illustration is useful for understanding some of the issues that arise when categorizing adherence, it relies on a single simulated data set. As such, it is unable to provide information on Type I error rates (false positive acceptance of null adherence effects) or Type II error rates (false negative rejection of true adherence effects) or biases in estimated effect sizes. We conducted a simulation study to provide insight into these issues.
Methodology
The current work employs simulation methods to study the effects of categorizing adherence data when it is assumed that adherence is a predictor of some positive health outcome. A simulation study allows the researcher to create data with known conditions so that performance of a statistical method can be examined, allowing one to better understand the properties of the statistical method being applied. Simulation studies are used to mimic the processes wanting to be studied while controlling parts of the process (e.g., setting the effect size or types of adherence categorization) and allowing other parts to be random (e.g., simulating random residuals with a known variance). Each facet of the process that is being studied is called a factor in the simulation study, and each factor can have two or more levels. Using the parlance of ANOVA, all factors are typically crossed with all other factors, yielding a full factorial simulation design. Thousands of data sets are simulated within each cell of the factorial design, and results are aggregated within each cell to avoid drawing conclusions that might stem from sampling fluctuations of a single simulated data set. The factors examined for this study are detailed in the next section. In the current work, we mimic the process of estimating the effect of adherence after categorizing adherence measured on the percent scale at 80 or at 50 % and 80 %, two categorizations used frequently in adherence research as shown previously.
Simulation study design
Data were simulated from a simple bivariate linear regression model, y = B 1 9 adherence + e. The residual variance e was distributed normally with a variance selected as a function of B 1 to achieve the desired effect size R 2 . The simulation factors, including the distribution of the adherence predictor, were as follows:
1. Distribution of adherence: Using a beta distribution, which ranges from 0 to 1, adherence was simulated according to the following shapes: uniform, n-shaped, u-shaped, negatively skewed, and positively skewed. To put scores on the percentage scale, adherence was multiplied by 100. 2. Categorization of adherence: For each simulated data set, we estimated the bivariate regression model when adherence was uncategorized, when it was dichotomized at 80 %, and when it was trichotomized at 50 and 80 %. 3. Effect size: We examined effect sizes of R 2 = 0 (which allowed us to examine Type I error rates), and R 2 = 0.1, 0.25, 0.5 (which allowed us to examine Type II error rates under a range of effect sizes). 4. Sample size: We examined sample sizes of 200, 500, and 1000. 5. Distribution of y: The outcome variable y was either continuous as described previously, or binary with prevalences of either 0.9, 0.25, or 0.5 (or, analogously by inversion, 0.1, 0.75, and 0.5). For binary outcome variable conditions, bivariate logistic regression models were fit to the simulated data, and McFadden's R 2 (McFadden, 1974; Menard, 2000) is used as the effect size estimate.
These factors combined to yield a simulation study with 5 (adherence distribution) 9 3 (adherence (non)categorization) 9 5 (effect size) 9 3 (sample size) 9 4 (outcome distribution) = 900 conditions. For each condition, 5000 data sets were simulated, yielding a total of 900 9 5000 = 4.5 million analyses. From each analysis, the following results were saved: the estimate of R 2 , the estimate(s) of B 1 , a binary indicator of whether a Type I error was made (for conditions where R 2 = 0), and a binary indicator of whether a Type II error was made (for conditions where R 2 [ 0). Data simulation and analysis of each simulated data set using linear or logistic regression was done in R 3.2.0 (R Core Team, 2015) . When evaluating p values, alpha (the Type I error rate) was set to 0.05.
Results
In the sections that follow, we present the Type I/Type II error rate and bias of R 2 results from the simulation study. As illustrated in the section on the counterintuitive interpretation of parameter estimates when dichotomizing adherence, the effect of adherence B 1 on the outcome y has a different meaning from the uncategorized adherence to the categorized adherence conditions. Hence, we do not summarize results for the estimates of B 1 .
Type I and Type II error rates
The results for Type I and Type II error rates are summarized in Table 2 . The empty cells (designated NA) in Table 2 follow a pattern. Type I errors (false positive conclusions that adherence is related to an outcome) are only defined when the true effect size is null (i.e., the simulation conditions where R 2 = 0). Analogously, Type II errors (false negative conclusions that adherence is not related to an outcome) are only defined when the true effect size is not null (i.e., the simulation conditions where Table 2 is stratified in columns by how adherence was treated in the analysis, whether it was left continuous, dichotomized, or trichotomized. Within each cell, the proportion of simulated data sets is given when a Type I and Type II error was made. This proportion is called the Type I (or Type II) error rate for the simulation study.
For Type I error, using the uncategorized adherence variable as the predictor yielded the Type I error rate specified a priori, i.e., alpha = 0.05. When adherence was dichotomized, the Type I error rate was attenuated in some conditions. When adherence was trichotomized, the Type I error rate was inflated, meaning researchers will falsely conclude that adherence was related to the outcome up to nearly twice as often as expected with an alpha of 0.05.
Categorizing adherence was even more problematic for Type II errors. These effects are interpreted relative to the Although most of these patterns hold for categorized adherence, the Type II error rates range from mildly to highly inflated relative to using uncategorized adherence. This reflects the known property that categorization will in general reduce statistical power (MacCallum et al., 2002) . The exception to the pattern described in the prior paragraph is the effect of the adherence distribution. The effect of the adherence distribution is especially large when dichotomizing adherence. Type II error rates exceeded 0.5 in several conditions such as low variance of binary outcomes, small sample size, or positively skewed adherence distribution. This makes conceptual sense-dichotomizing discards the maximum amount of information while still having a nonzero variance. The trichotomized classifications are not as severely affected as dichotomized results. However, this observation should not be taken as justification for trichotomizing instead of dichotomizing. In addition to the warnings and limitations discussed in the section on the counterintuitive interpretation of parameter estimates, Type II error rates can still be highly inflated relative to estimating models using uncategorized adherence.
Bias in effect size estimates
The bias of R 2 is the average of the differences between the R 2 estimates and the true values of R 2 from which the data Absolute bias is the average of the differences between estimated R 2 and the true value of R 2 . Relative bias is the average of the ratio of estimated R 2 to true R 2 (e.g., if estimated effect size is 0.2 and the true effect size is 0.5, 0.2/0.5 = 0.4, or, the estimate is only 40 % of the true value). Also note that rows average over adherence distribution and sample size, as these had relatively small effects on bias. For the binary outcome conditions, logistic regression was used and McFadden's R 2 was calculated. NA indicates relative bias that was not computable due to division by zero were simulated. Table 3 provides the absolute and relative bias for each of simulated values of R 2 . As with the results in Table 2 , categorizing adherence almost always yields greater bias than when fitting models with uncategorized adherence. Dichotomizing yields greater bias than trichotomizing. Bias is also almost always negative, indicating that the magnitude of the effect of adherence on the outcome will almost always be underestimated. The relative bias indicates what percentage of the true effect size was recovered on average. For example, when adherence was not categorized and the outcome variable (y) was continuous, there was no bias (i.e., relative bias = 1). When trichotomizing adherence, the estimated effect sizes were 82-100 % of the true R 2 , while dichotomizing only estimated 44-50 % of the true effect size on average. Also observe that the larger the effect size, the larger the bias in general. This is simply due to larger effects having a larger starting point from which to be biased.
Discussion
Across health conditions, including serious mental illnesses and physical health conditions like diabetes, HIV, and cardiovascular disease, adherence to prescribed pharmacological medication regimens are often the primary evidencebased or guideline-recommended interventions available. However, for many health conditions, when evaluating the effects of medication adherence on subsequent health states, researchers sometimes analyze a categorized version of the original continuous adherence variable. Moreover, the cut points used to categorize adherence appear to be selected without strong empirical or clinical justifications, and even when prior research cautions against categorizing continuous variables because it reduces statistical power and can increase bias (Peterson et al., 2007; MacCallum et al. 2002) . We investigated, through a simulation study, the effects of categorizing a continuous adherence variable under multiple conditions, including categorizing adherence at 80 or at 50 % and 80 %, two categorizations used frequently in adherence research. The results of the simulation provide concrete examples of the negative impact of categorizing adherence, which is often measured on a proportion or percentage scale. The primary implications for future adherence research are first, to measure adherence continuously and second, to estimate the effects of adherence on outcomes without categorizing it.
The results of the current study also have implications for interpreting prior adherence research. First, reported estimates of the effects of adherence are prone to misinterpretation. As noted previously, interpretations of categorized adherence that compare, for example, being adherent less than 80 % of the time to being adherent 80 % or more of the time, are likely to be incorrect. Instead, the interpretation is correctly based on moving from the average adherence in one group to the average adherence in another group. In addition, within each category of categorized adherence there is variation around the mean-level of adherence. When adherence is categorized, this variation is discarded, which was shown in the simulation study to reduce statistical power. Moreover, this practice treats patients with more or less adherence than the mean level in the categorization as the same. It is unclear how this artificial reduction of heterogeneity in adherence might impact clinical or economic outcome research.
Next, correcting the interpretation of the effects of categorized adherence will not alleviate the reduced statistical power and increased bias in estimated effect sizes shown via a simulation study. That is, although it would be an improvement to see the effects of adherence interpreted correctly in future research, results from the current simulation study show that the outcomes reported from any individual study may be biased to such an extent that they are incorrect, for example, in identifying a significant effect when the true effect is null, or at least misstating the true magnitude of the adherence effect. Still, a correct interpretation of biased or incorrect results does not satisfactorily address the issue brought on by categorizing adherence in the first place.
Third, the distribution of adherence when measured on a continuous scale greatly impacts the interpretation of categorized adherence effects. Consequently, meta-analyses focusing on parameter estimates for effects of categorized adherence on outcomes will not yield comparable estimates unless the distribution of adherence when measured on a continuous scale is the same across studies. Unfortunately, these distributions are not typically reported in adherence research. Fourth, even though meta-analyses of effect sizes such as R 2 might still be valid, the estimated effect sizes when categorizing adherences will be underestimated. Fifth, while increasing sample sizes does improve power relative to lower sample size, larger sample size alone is insufficient to ameliorate the negative consequences of categorizing adherence relative to analyses when a continuous measure of adherence is not categorized. Sixth, although trichotomization theoretically throws away less information than does dichotomization (as evidenced by trichotomization having lower Type II error raters than did dichotomization), trichotomization had higher Type I error rates than did dichotomization. Finally, the simulation study showed that categorizing adherence can dramatically decrease statistical power, giving researchers less of what they want when endeavoring to estimate the effect of adherence on important outcomes.
Although the results of this study are primarily cautionary, the recommendations to measure adherence on a continuous scale and not categorize it prior to estimating its effects on outcomes represent a first step in improving the measurement and modeling of adherence. We limited our investigation to the situation in which adherence was an independent variable. In standard regression models, one does not make distributional assumptions about the independent variable. Further investigation is required to develop guidelines on how to model adherence as a dependent variable. This will be required when adherence is treated as a cross-sectional outcome (e.g., when estimating the effect of predictors of adherence such as affordability, access, or concurrent routine, nonpharmacologic interventions), when adherence is treated as a mediator (e.g., when estimating the effect of something thought to be related to both adherence and some primary health outcome), or when adherence is treated as an longitudinal outcome (e.g., when estimating how changes in adherence impact changes in health outcomes).
Another limitation of this work was the assumption of a linear relationship between adherence and the simulated outcome variable. If achieving some cut at adherence such as 80 % had a truly meaningful impact on health outcomes, this might be detectable via an inflection point in a nonlinear relationship between adherence and a health outcome. Although standard methods for examining nonlinear relationships are illustrated in regression textbooks (e.g., adding quadratic or higher order polynomial terms for adherence), these do not appear to be routinely practiced among adherence researchers. Although a topic for future research, another situation in which categorization may be justified is in extremely separated u-shaped distributions. Unless situations like this are observed to occur in practice, we advise against approaches that are inherently categorical (i.e., binary self-report measures) when possible. Our work is also limited to the two categorizations used herein. In theory, having more categories than three may yield results less deleterious than dichotomization or trichotomization, but additional research is required to assess this posibility.
In summary, the results of this work have immediate implications for adherence research across both physical and mental health conditions. Correctly estimating the effects of adherence will help yield more effective treatments, substantial cost savings, and improved quality of life for patients.
